Prescription Eye Drops Recalled for Manufacturing Control Deviations
Akorn, Inc. is voluntarily recalling over 2 million bottles of Tobramycin Ophthalmic Solution due to Current Good Manufacturing Practice deviations affecting four product lots distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for Current Good Manufacturing Practice deviations affecting 2.1 million bottles of an ophthalmic solution distributed nationwide. While no illnesses have been reported, ophthalmic solutions are risk-of-harm products requiring strict manufacturing controls due to the sensitivity of eye tissues.
Plain-English summary
Tobramycin Ophthalmic Solution, USP 0.3%, 5 mL per dropper bottle, manufactured by Akorn, Inc. of Lake Forest, Illinois, is being recalled. The product carries NDC (National Drug Code) 17478-290-10, and approximately 2,095,068 bottles are affected.
The recall was initiated by Akorn, Inc. due to Current Good Manufacturing Practice (CGMP) deviations. The recall applies to four specific lots: Lot 1C56A (expiration 2/28/2023), Lot 1J50A (expiration 8/31/2023), Lot 1K61A (expiration 9/30/2023), and Lot 1M27A (expiration 11/30/2023).
The product was distributed nationwide in the United States. The firm voluntarily initiated the recall on October 13, 2022, which was classified as FDA Class II by the FDA on January 13, 2023. The recall status is ongoing.
Patients and healthcare providers who have or use affected lots should consult with their prescribing provider or pharmacist regarding this recall.
The recalled product
- Product
- Tobramycin Ophthalmic Solution, USP, 0.3%, 5 mL per dropper bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. NDC 17478-290-10
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot: 1C56A
- EXP 2/28/2023
- 1J50A
- EXP 8/31/2023
- 1K61A
- EXP 9/30/2023
- 1M27A
- EXP 11/30/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27